{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:50:25Z","timestamp":1791665425619,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009448","name":"University of Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101456","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:50:59Z","timestamp":1791244259000},"page":"101456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hereditary cancer syndromes as a model for precision oncology: the paradigms of HRD and MSI"],"prefix":"10.1016","volume":"49","author":[{"given":"Chiara","family":"Della Pepa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialaura","family":"Zitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Caliendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Stilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101456_bib0001","doi-asserted-by":"crossref","first-page":"114","DOI":"10.14694\/EdBook_AM.2015.35.114","article-title":"Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different?","author":"Tan","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101456_bib0002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101456_bib0004","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101456_bib0006","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101456_bib0007","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101456_bib0008","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101456_bib0009","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101456_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101456_bib0012","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101456_bib0013","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.ctarc.2026.101456_bib0014","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101456_bib0015","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0016","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat. Cancer"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101456_bib0017","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.3390\/cancers16203447","article-title":"PARP inhibitors in pancreatic cancer with homologous recombination repair gene mutations: a single-institution experience","volume":"16","author":"Miao","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s44276-025-00122-9","article-title":"Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review","volume":"3","author":"Wang","year":"2025","journal-title":"BJC Rep."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101456_bib0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"issue":"16 suppl","key":"10.1016\/j.ctarc.2026.101456_bib0022","article-title":"TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s)mutations in BRCA1 or BRCA2. Abstract 1021, ASCO","volume":"42","author":"Tung","year":"2024","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0023","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41698-024-00634-6","article-title":"Phase II study of talazoparib in advanced cancers with BRCA1\/2, DNA repair, and PTEN alterations","volume":"8","author":"Piha-Paul","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101456_bib0024","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101456_bib0025","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101456_bib0026","doi-asserted-by":"crossref","first-page":"S1225","DOI":"10.1016\/j.annonc.2024.08.2272","volume":"35","author":"Nicum","year":"2024","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101456_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/genes10080565","article-title":"PARP inhibitors in prostate cancer\u2014the preclinical rationale and current clinical development","volume":"10","author":"Virtanen","year":"2019","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0028","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101456_bib0029","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101456_bib0030","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"issue":"10398","key":"10.1016\/j.ctarc.2026.101456_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"suppl 17","key":"10.1016\/j.ctarc.2026.101456_bib0032","article-title":"Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101456_bib0033","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3390\/ijms23073871","article-title":"The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy","volume":"23","author":"Maiorano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101456_bib0034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-031-30065-3_12","article-title":"Combining PARP inhibition and immunotherapy in BRCA-associated cancers","volume":"186","author":"Shapiro","year":"2023","journal-title":"Cancer Treat. Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009032","article-title":"PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer","volume":"12","author":"Xia","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101456_bib0036","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101456_bib0037","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0038","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0039","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0040","series-title":"LBA5506 - FIRST\/ENGOT-OV44: a Phase 3 Clinical Trial of Dostarlimab (dost) and Niraparib (nira) in First-Line (1L) Advanced Ovarian Cancer (aOC)","author":"Hardy-Bessard","year":"2025"},{"issue":"8_Supplement","key":"10.1016\/j.ctarc.2026.101456_bib0041","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT145","article-title":"Abstract CT145: olaparib \u00b1 atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial","volume":"83","author":"Fanucci","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0042","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101456_bib0043","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers15123095","article-title":"Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer","volume":"15","author":"Paik","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101456_bib0044","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-19-3841","article-title":"Targeting DNA repair to drive immune responses: it's time to reconsider the strategy for clinical translation","volume":"26","author":"Takahashi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without Olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0046","first-page":"608","article-title":"Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology","volume":"2","author":"Mweempwa","year":"2019","journal-title":"Cancer Drug. Resist."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0047","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101456_bib0048","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41418-025-01457-z","article-title":"STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage","volume":"32","author":"Sun","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ctarc.2026.101456_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104233","article-title":"Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors","volume":"193","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101456_bib0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","article-title":"Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer","volume":"20","author":"Tang","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2026.101456_bib0051","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","article-title":"EFFORT: efficacy of adavosertib in parp resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer","volume":"39","author":"Westin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0052","article-title":"ADAGIO: a phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma","author":"Liu","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101456_bib0053","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1535-7163.MCT-23-0681","article-title":"Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues","volume":"23","author":"Baker","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"1 Suppl","key":"10.1016\/j.ctarc.2026.101456_bib0054","article-title":"Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with cytotoxic chemotherapy or novel anti-cancer agents (AToM Study)","volume":"17","author":"Abida","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0055","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0056","first-page":"33","article-title":"Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer","volume":"10","author":"Eshleman","year":"1995","journal-title":"Oncogene"},{"issue":"7407","key":"10.1016\/j.ctarc.2026.101456_bib0057","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.ctarc.2026.101456_bib0058","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6349","key":"10.1016\/j.ctarc.2026.101456_bib0059","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101456_bib0060","series-title":"FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/Site-Agnostic Indication","year":"2017"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101456_bib0061","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0062","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101456_bib0063","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0064","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0065","series-title":"Plymouth Meeting","article-title":"NCCN clinical practice guidelines in oncology: uterine neoplasms. Version 3.2025","year":"2025"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101456_bib0068","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101456_bib0069","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2024.1288061","article-title":"Microsatellite instability is highly prevalent in older patients with colorectal cancer","volume":"11","author":"Jakob","year":"2024","journal-title":"Front. Surg."},{"issue":"9-S","key":"10.1016\/j.ctarc.2026.101456_bib0071","first-page":"97","article-title":"Microsatellite instability in colorectal cancer","volume":"89","author":"De' Angelis","year":"2018","journal-title":"Acta Biomed."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0072","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom","year":"2018","journal-title":"Br. J. Surg."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101456_bib0073","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0074","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101456_bib0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cas.14798","article-title":"Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors","volume":"112","author":"Akagi","year":"2021","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0076","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101456_bib0077","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2022.12.008","article-title":"Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: a systematic review and meta-analysis","volume":"170","author":"Mitric","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"7447","key":"10.1016\/j.ctarc.2026.101456_bib0082","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101456_bib0083","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101456_bib0084","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1093\/hmg\/ddu058","article-title":"New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis","volume":"23","author":"Valle","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0085","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0086","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-024-01939-5","article-title":"A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon\/polymerase delta (POLE\/POLD1) mutation","volume":"9","author":"Jin","year":"2024","journal-title":"Signal Transduct. Target. Ther"},{"key":"10.1016\/j.ctarc.2026.101456_bib0087","article-title":"166\u2005POLE\/POLD1 mutations as predictive biomarkers for immunotherapy response: insights from a pan-cancer real-world dataset","volume":"12","author":"Franch-Exposito","year":"2024","journal-title":"J. Immun. Therap. Cancer."},{"key":"10.1016\/j.ctarc.2026.101456_bib0088","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101456_bib0089","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101456_bib0091","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101456_bib0092","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-21-0401","article-title":"A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H\/dMMR gastrointestinal tumors","volume":"27","author":"Chida","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101456_bib0093","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0094","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13046-023-02882-z","article-title":"MBD4 loss results in global reactivation of promoters and retroelements with low methylated CpG density","volume":"42","author":"Papin","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0095","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41431-023-01418-5","article-title":"MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes","volume":"31","author":"Terradas","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ctarc.2026.101456_bib0096","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2022.06.033","article-title":"MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients","volume":"173","author":"Saint-Ghislain","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101456_bib0097","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2018-05-852566","article-title":"MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML","volume":"132","author":"Sanders","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0098","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/cancers15102774","article-title":"Tackling of immunorefractory tumors by targeting alternative immune checkpoints","volume":"15","author":"Dulal","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0099","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101456_bib0101","series-title":"FDA Approves Opdualag (Nivolumab and Relatlimab-rmbw), a Fixed-Dose Combination, for Unresectable or Metastatic Melanoma","year":"2022"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101456_bib0102","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9602","article-title":"A phase 3 trial of fianlimab (anti\u2013LAG-3) plus cemiplimab (anti\u2013PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma","volume":"41","author":"Baramidze","year":"2023","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101456_bib0103","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8 Suppl 2","key":"10.1016\/j.ctarc.2026.101456_bib0104","article-title":"SKYSCRAPER-01: a phase III, randomized trial of tiragolumab (tira) plus atezolizumab (atezo) versus placebo (pbo) plus atezolizumab in patients with previously untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC","volume":"85","author":"Peters","year":"2025","journal-title":"Cancer Res."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101456_bib0105","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/14796694.2024.2355863","article-title":"IMbrave152\/SKYSCRAPER-14: a phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma","volume":"20","author":"Badhrinarayanan","year":"2024","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0106","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1186\/s12885-023-11534-6","article-title":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer","volume":"23","author":"Roussot","year":"2023","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101456_bib0107","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0108","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","article-title":"VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response","volume":"15","author":"Thisted","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101456_bib0109","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0110","article-title":"Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101456_bib0111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors","volume":"13","author":"Luke","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101456_bib0112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41419-024-06638-1","article-title":"STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0113","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0114","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101456_bib0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41698-024-00672-0","article-title":"The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors","volume":"8","author":"Incorvaia","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0116","article-title":"PARP inhibitor insensitivity to BRCA1\/2 monoallelic mutations in microsatellite instability-high cancers","volume":"6","author":"Sokol","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0117","article-title":"Hotspot BRCA1\/2 mutations in tumors with microsatellite instability suggest passenger mutation status and may confound targeted therapy selection","volume":"9","author":"Rajagopal","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0118","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1159\/000540419","article-title":"Complete response to pembrolizumab in a patient with castration-resistant prostate cancer with both BRCA positivity and a high frequency of microsatellite instability: a case report","volume":"17","author":"Hirano","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.ctarc.2026.101456_bib0119","article-title":"Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer","volume":"21","author":"Higa","year":"2025","journal-title":"Curr. Probl. Cancer Case Rep."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:22:57Z","timestamp":1791663777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":115,"alternative-id":["S2468294226003667"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101456","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary cancer syndromes as a model for precision oncology: the paradigms of HRD and MSI","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101456"}}